The European Medicines Agency has provided further guidance to help companies to prepare for Brexit. A Q&A published yesterday gives further detail on the transfer of centralised marketing authorisations for medicines and variations to effect changes to manufacturing activities, batch release function, qualified person for pharmacovigilance etc.

The EMA’s additional guidance can be found here: